143 related articles for article (PubMed ID: 30880770)
21. Fractal analysis of contrast-enhanced CT images for preoperative prediction of malignant potential of gastrointestinal stromal tumor.
Kurata Y; Hayano K; Ohira G; Narushima K; Aoyagi T; Matsubara H
Abdom Radiol (NY); 2018 Oct; 43(10):2659-2664. PubMed ID: 29500645
[TBL] [Abstract][Full Text] [Related]
22. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer.
Xi Y; Guo R; Hu J; Zhang M; Zhang X; Li B
Nucl Med Commun; 2014 Nov; 35(11):1112-8. PubMed ID: 25098308
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors.
Yoshikawa K; Shimada M; Kurita N; Sato H; Iwata T; Morimoto S; Miyatani T; Kashihara H; Takasu C; Matsumoto N
Surg Today; 2013 Oct; 43(10):1162-7. PubMed ID: 23143169
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
[TBL] [Abstract][Full Text] [Related]
25. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to ¹⁸F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors.
Cho MH; Park CK; Park M; Kim WK; Cho A; Kim H
PLoS One; 2015; 10(10):e0141413. PubMed ID: 26509967
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
28. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
[TBL] [Abstract][Full Text] [Related]
29. Value of
Wu B; Zhang Y; Tan H; Shi H
Abdom Radiol (NY); 2019 Jul; 44(7):2430-2435. PubMed ID: 30944961
[TBL] [Abstract][Full Text] [Related]
30. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
31. Prospective analysis of 18F-FDG PET/CT predictive value in patients with low rectal cancer treated with neoadjuvant chemoradiotherapy and conservative surgery.
Niccoli-Asabella A; Altini C; De Luca R; Fanelli M; Rubini D; Caliandro C; Montemurro S; Rubini G
Biomed Res Int; 2014; 2014():952843. PubMed ID: 24877151
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer.
Oku S; Nakagawa K; Momose T; Kumakura Y; Abe A; Watanabe T; Ohtomo K
Ann Nucl Med; 2002 Sep; 16(6):409-16. PubMed ID: 12416580
[TBL] [Abstract][Full Text] [Related]
34. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
Kim SJ; Lee SW
J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
[TBL] [Abstract][Full Text] [Related]
35. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
Otomi Y; Otsuka H; Morita N; Terazawa K; Furutani K; Harada M; Nishitani H
J Med Invest; 2010 Aug; 57(3-4):270-4. PubMed ID: 20847527
[TBL] [Abstract][Full Text] [Related]
36. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
37. Imaging features of primary anorectal gastrointestinal stromal tumors with clinical and pathologic correlation.
Koch MR; Jagannathan JP; Shinagare AB; Krajewski KM; Raut CP; Hornick JL; Ramaiya NH
Cancer Imaging; 2013 Feb; 12(3):557-65. PubMed ID: 23400107
[TBL] [Abstract][Full Text] [Related]
38. The relationship between HER2 expression and
Ozen A; Tatar G
Hell J Nucl Med; 2022; 25(1):5-10. PubMed ID: 35388798
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT.
Watabe T; Tatsumi M; Watabe H; Isohashi K; Kato H; Yanagawa M; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2012 Apr; 26(3):222-7. PubMed ID: 22187313
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience.
Kim DH; Kim SY; Lee HJ; Song BS; Kim DH; Cho JB; Lim JS; Lee JA
Cancer Res Treat; 2011 Sep; 43(3):170-5. PubMed ID: 22022294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
